Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Analysis of Suicidal Behavior Among Children and Adolescents in the Auvergne-Rhone-Alpes Region During the Covid 19 Pandemic Period

NCT07302295 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-05-06
Last updated
2026-05-18

Condition(s) studied

SuicidalityCOVID -19

Investigational drug(s) / intervention(s)

Aggregated data collectionData collection and qualitative interview

Aggregated data collection: The demographic and diagnostic characteristics will be collected in aggregate form nafrom digital services departments or medical information departments of participating hospitals.

Data collection and qualitative interview: The psychopathological and socioeconomic characteristics will be collected. For subjects who agreed, they will participate in interviews and/or focus groups. Parent's subjects who agreed will be part of focus groups too.

Study summary

In 2020, the world is hit by a global health crisis due to a pandemic following the appearance of Sars-cov-2 or "covid-19". This pandemic was accompanied by a constant fear of contamination and death, relayed by the media. In France, the government proposed in response to the arrival of this virus on French territory. This policy was implemented in different ways over 3 distinct periods: strict containment at the start of the epidemic, then a "lighter" one, and finally a period of social restrictions without between these periods. This policy had a direct and rapid impact on the population's daily routines. Children and adolescents, are more susceptible to psychological trauma, as stress has a direct and psychic development. Studies have shown deleterious impact of the French health situation on the paediatric population. They point to an increase of psychological disorders such as depression and anxiety in the under -20s population, and an increase in suicidal gestures over the 2020-2021 period, with rates remaining higher than in previous years. Suicide is the 2nd leading cause of death in the population aged 15-24.

Studies continue to focus on the incidence of suicidal gestures of suicidal gestures and psychological disorders, and few of them examine the factors linked to the increase in these incidences, the traumatic impact or the story of the trajectory. Similarly, the few studies focus only on the population aged 12 and over, and in some cases, do not distinguish between age groups (15-24 or under 20).

Investigators believe that the various periods of social restrictions and eco-anxiety caused by the pandemic may have influenced suicidal behaviour in this population.

The main objective of this study is to investigate the clinical and socio-economic characteristics of the pediatric population who experienced suicidal behaviors in the Auvergne Rhone Alpes region during the covid 19 pandemic.

Eligibility

Sex
ALL
Min age
8 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * The population (subjects and controls) will be divided into age categories: * Pre-adolescents (≥ 8 years and \< 11 years) * Adolescents (≥ 11 years and \< 15 years) * Older adolescents (≥ 15 years and \< 18 years) Subjects with suicidal behavior during the health crisis (Group 1): * Age \> 8 years and \< 18 years during the period 2020 to 2022. * Admitted to pediatric emergency departments or hospitalized in a care unit (CHU, general hospitals) in the AURA region during 2020, 2021, and/or 2022 for suicidal behavior (defined as suicidal ideation and/or suicide attempt and/or self-harm/self-poisoning with suicidal intent). Subjects with suicidal behavior during the health crisis with qualitative interviews (Group 1b): * Age \> 8 years and \< 18 years during the period 2020 to 2022. * Admitted to pediatric emergency departments or hospitalized in a care unit (CHU, general hospitals) in the AURA region during 2020, 2021, and/or 2022 for suicidal behavior (defined as suicidal ideation and/or suicide attempt and/or self-harm/self-poisoning with suicidal intent). * Randomly selected from the population of Group 1. * For whom the parent(s) and/or the subject have signed informed consent. Controls with suicidal behavior before the health crisis (Group 2): * Age \> 8 years and \< 18 years during the period 2018 to 2019. * Admitted to pediatric emergency departments or hospitalized in a care unit (CHU, general hospitals) in the AURA region during 2018 and/or 2019 for suicidal behavior (defined as suicidal ideation and/or suicide attempt and/or self-harm/self-poisoning with suicidal intent). Exclusion Criteria: \- Subjects with Suicidal Behavior during the Health Crisis with and without Qualitative Interviews (Group 1 and 1b): • Admitted to pediatric emergency services or hospitalized in a healthcare facility (university hospital center, general hospital) in the AURA region for a psychiatric reason other than suicidal behavior during the period from 2020 to 2022. Controls with Suicidal Behavior before the Health Crisis (Group 2): * Admitted to pediatric emergency services or hospitalized in a healthcare facility (university hospital center, general hospital) in the AURA region for a psychiatric reason other than suicidal behavior during the period from 2018 to 2019. * Intercurrent illness with a life expectancy of less than 24 hours. For Group 1: * Pregnant, postpartum, or breastfeeding women. * Persons deprived of liberty by judicial or administrative decision. * Adults subject to a legal protection measure (guardianship, curatorship). * Persons not affiliated with a social security scheme or beneficiaries of a similar scheme. * Persons who do not understand and do not speak French.

Primary outcome measure(s)

  • Demographic and diagnostic characteristics — Baseline
    The following demographic and diagnostic characteristics will be collected in aggregate form for the entire population of children and adolescents who engaged in suicidal behavior during the health crisis and in the two preceding years: * Age, gender, place of residence, * ICD-10 diagnosis and referral, * Type of suicidal behavior (ideation, self-harm, suicide attempt), * Periods of social restrictions (lockdown, curfew, vaccine pass).

Trial sites (4)

FacilityCityRegionStatus
Hospices Civils de Lyon - Hôpital Femme Mère Enfant- Service de pédopsychiatrie de l'enfant et de l'adolescent Bron France Recruiting
CHU de Clermont-Ferrand - Service de psychiatrie de l'enfant et de l'adolescent Clermont-Ferrand France Not Yet Recruiting
CHU de Grenoble - Service de psychiatrie de l'enfant et de l'adolescent Grenoble France Not Yet Recruiting
CHU de Saint-Etienne - Urgences psychiatriques Saint-Etienne France Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07302295 on ClinicalTrials.gov ↗ ← All trials in France